A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2004
12/02/2004	US20040242873 Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same
12/02/2004	US20040242871 Nitric oxide synthease inhibitors; antiinflamamtory agents; analgesics; inflamamtory bowel disorders; antiarthritic agents;
12/02/2004	US20040242868 Controlling cytokines; antiinflammatory agents; rheumatic disoreders; skin disorders; respiratory system disorders; Alzheimer's disease; Parkinson's disease; Huntington"s disease ; amyotrophic lateral sclerosis
12/02/2004	US20040242853 Glp-1 exendin-4 peptide analogs and uses thereof
12/02/2004	US20040242701 Amines as ant-alcoholism agents
12/02/2004	US20040242698 Analeptic and antidepressant combinations
12/02/2004	US20040242695 N-(2-n-propylpentanoyl)taurin-N',N'-dimethylamide; epilepsy, psychotic and bipolar disorders, chronic pain, headaches, migranes, brain ischemia; high bioavailability; antiepileptic, antiischemic agents
12/02/2004	US20040242692 4-(3-(2,6-Dimethoxybenzyloxy)phenyl)-4-oxobutyric acid or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis
12/02/2004	US20040242685 Administering -4-benzyloxy-3,5-dimethoxy-N-[(1-dimethylaminocyclopentyl)methyl]benzamide or derivatives for treating disorders responsive to inhibition of the GlyT-2 transporter, such as muscle spasticity, epilepsy and acute, chronic and neuropathic pain
12/02/2004	US20040242672 Pyrrolidine derivatives
12/02/2004	US20040242671 Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug
12/02/2004	US20040242652 Beta benzyloxyaspartate derivatives with amino group on benzene ring
12/02/2004	US20040242647 Use of organic compounds
12/02/2004	US20040242636 Enzyme inhibitors as antiinflammatory ageents for psoriasis, obesity
12/02/2004	US20040242631 PI-3 kinase inhibitor prodrugs
12/02/2004	US20040242627 2-Iminoimidazole derivatives (1)
12/02/2004	US20040242616 reducing the central nervous system activity of a morphine-like opioid, comprising linking the nitrogen atom of the morphine-like opioid to a radical
12/02/2004	US20040242605 Medicine containing pyrimidine derivative
12/02/2004	US20040242598 Phosphodiesterase 4 inhibitors
12/02/2004	US20040242594 Prodrugs of antidepressants and their use for treating depressions
12/02/2004	US20040242592 2-Substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors
12/02/2004	US20040242589 3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
12/02/2004	US20040242587 Pyrrolo[1,2-b]pyridazine compounds
12/02/2004	US20040242586 gamma-aminobutyric acid receptor ligands, prepared by reacting [2-(2-(trimethylsilanyl)ethoxymethyl)-2H-[1,2,4]triazol-3-yl]methanol and 7-tert-butyl-6-chloro-3-(2-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazine, then deprotecting, to form drugs used as anticonvulsants and anxiolytic agents
12/02/2004	US20040242584 Muscarinic agonists
12/02/2004	US20040242576 Urea substituted benzothiazoles
12/02/2004	US20040242575 for use with various disorders including sleep disorders; depression; cardiovascular disorders; pain; neurodegenerative disorders; psychiatric disorders etc.
12/02/2004	US20040242573 Novel compounds
12/02/2004	US20040242571 Novel benzothiazine derivatives, their preparation and use
12/02/2004	US20040242570 Conjugated psychotropic drugs and uses thereof
12/02/2004	US20040242565 Medicinal composition for prevention of or treatment for cerebrovascular disorder and cardiopathy
12/02/2004	US20040242564 1,2,3,4-tetrahydroisoquinolines derivatives
12/02/2004	US20040242558 Pyridylether derivatives, their preparation and use
12/02/2004	US20040242553 Drugs to improve synaptic transmission
12/02/2004	US20040242552 New use of antimineralocorticoid compounds against narcotic withdrawal syndrome
12/02/2004	US20040242547 Arylazo-substituted imidazole for the treatment of stress urinary incontinence
12/02/2004	US20040242515 Trp1, mct, or ftz-f1 homologous proteins involved in the regulation of energy home-ostasis
12/02/2004	US20040242511 Method
12/02/2004	US20040242508 Novel hydroxyalkyl indolocarbazole derivatives, preparation method and pharmaceutical compositions containing the same
12/02/2004	US20040242506 Formed from paroxetine hydrochloride and ammonium glycyrrhyzinate by precipitation, spray, vacuum or freeze drying, or evaporation to glass; solid or oil; masks the bitter taste of paroxetine and has a distinctive licorice flavor; antidepressants; Parkinson's disease
12/02/2004	US20040242503 Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease
12/02/2004	US20040242497 Ammonium glycyrrhyzinate masks the bitter taste of paroxetine hydrochloride and has a distinctive licorice flavor; dispersable powders or tablets; antidepressants; Parkinson's disease
12/02/2004	US20040242493 Neurotensin active 2,3,diaryl-pyrazolidine derivatives
12/02/2004	US20040242491 For use in the treatment of gout and related symptoms or in the amelioration of symptoms related to a high level of uric acid such as muscle spasm, localized swelling, inflammation, joint pains, muscle fatigue, or as a dietary supplement
12/02/2004	US20040242479 Compounds capable of affecting differentiation, proliferation, regeneration, plasticity and survival of cells
12/02/2004	US20040242472 Use of artemin, a member of the gdnf ligand family
12/02/2004	US20040242462 Detecting that individual's Tob gene, transcript and/or protein and comparing with normal Tob gene, transcript and/or protein, differences present indicating that the probability of that individual suffering from amnesia
12/02/2004	US20040242459 Method for treating inflammatory diseases by administering a ppar-delta agonist
12/02/2004	US20040242457 Use of anti-glaucoma drugs to treat visual defects associated with the use of a GABAergic agent
12/02/2004	US20040242455 which exerts potent and selective activated blood coagulation factor X inhibitory activity and is useful for prevention or treatment of disease associated therewith
12/02/2004	US20040242452 For effecting mental control through psycho-sedation or psycho-stimulation
12/02/2004	US20040241805 Cell surface binding protein for use in treatment, diagnosis and prevention of cancer, inflammation, autoimmunity, allergy, asthma and nervous system disorders
12/02/2004	US20040241803 25 human secreted proteins
12/02/2004	US20040241792 Substrates and assays for beta-secretase
12/02/2004	US20040241757 Membrane protein for use in identifying modulators for treatment and prevention neuronal trauma and disorders
12/02/2004	US20040241671 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their us as medicines
12/02/2004	US20040241639 Human tachykinin-related splice variants and compositions thereof
12/02/2004	US20040241255 Pharmaceutical composition containing valerina officinalis extract
12/02/2004	US20040241240 A copolymer of N-vinyl-2-pyrrolidone with e.g., ethylhexyl acrylate and 1,6-hexanediol diacrylate, enhances absorption of a hardly soluble drug such as one having an ergoline skeleton, e.g., a pergolide or a bromocriptine; improved skin permeability
12/02/2004	US20040241205 capsules comprising biocompatible silica sol-gel matrices that encapsulate chemical intermediates or prodrugs that convert when contacted with tissues and/or fluids; grafting encapsulated L-amino acid decarboxylase in the brain to convert L-dopa to dopamine for prophylaxis of Parkinson's disease
12/02/2004	US20040241164 Use of antibodies having high affinity for soluble ab to treat conditions and diseases related to ass
12/02/2004	US20040241156 Gene expression inhibition; solid phase synthesis; drug screening; for treating cancer, central nervous system disorders, and chronic obstructive pulmonary disorder
12/02/2004	US20040241135 Therapeutic compositions including bio-availability enhancers
12/02/2004	DE202004009180U1 Formulation comprising glycine-containing gel, useful, by external or internal application, for treatment or prevention of e.g. allergy, sunburn and stress
12/02/2004	CA2532059A1 Triaza-spiro compounds as nociceptin analogues and uses thereof
12/02/2004	CA2526631A1 Migraine remedy
12/02/2004	CA2526493A1 Means for preventing and treating cellular death and their biological applications
12/02/2004	CA2526374A1 2-aminoquinoline derivatives
12/02/2004	CA2526201A1 Glycosaminoglycans for treatment emotional dysfunctions
12/02/2004	CA2526173A1 Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity
12/02/2004	CA2526027A1 Process for making spirolactone compounds
12/02/2004	CA2525102A1 Benzothiazole derivatives and use thereof in the treatment of diseases relates to the adenosine a2a receptor
12/02/2004	CA2524870A1 Pharmaceutical combination comprising modafinil and another drug
12/01/2004	EP1481992A2 Humanized antibodies that sequester amyloid beta peptide
12/01/2004	EP1481989A1 A-33 related antigens and their pharmacological uses
12/01/2004	EP1481976A1 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
12/01/2004	EP1481969A1 Piperidine derivative compounds and drugs containing the compounds as the active ingredient
12/01/2004	EP1481690A1 Therapeutic compositions including bio-availability enhancers
12/01/2004	EP1481679A1 Antidepressant
12/01/2004	EP1481673A1 Medicinal compositions containing gabapentin or pregabalin and n-type calcium channel antagonist
12/01/2004	EP1481668A1 Use of anti-glaucoma drugs to treat visual field defects associated with the use of a GABAergic agent
12/01/2004	EP1481667A1 NEP inhibitors for the treatment of female sexual dysfunction
12/01/2004	EP1481250A2 Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents
12/01/2004	EP1481067A1 Expression cassette for persistence of expression of a gene of interest in muscle cells
12/01/2004	EP1481008A2 Anti-amyloid beta antibodies and their use
12/01/2004	EP1481007A2 Spheron components useful in determining compounds capable of treating symptoms of alzheimer's disease, treatments and animal models produced therefrom
12/01/2004	EP1481001A2 Prion inhibiting peptides and derivatives thereof
12/01/2004	EP1480999A2 (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
12/01/2004	EP1480993A2 Desaturase genes, enzymes encoded thereby, and uses thereof
12/01/2004	EP1480986A1 Novel benzothiazine and benzothiadiazine derivatives, method for preparing same and pharmaceutical compositions containing same
12/01/2004	EP1480983A1 Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl-6,7,8,9-tetrahydropydimido[1,2-a]pyrimidin-4-one derivatives
12/01/2004	EP1480981A1 1-(alkyl), 1-(heteroaryl)alkyl and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1h)-one derivatives
12/01/2004	EP1480978A1 Process for preparing 3-(2-(4-(6-fluorobenzo(d) isoxazol-3-yl)-piperidin-1yl)-ethyl)-2-methyl-6,7,8,9-tetrahydro-4h-pyrido-(1,2-a) pyrimidin-4-one
12/01/2004	EP1480977A2 Substituted aryl compounds for treatment of disease
12/01/2004	EP1480974A1 Heterocyclylmethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors
12/01/2004	EP1480973A1 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
12/01/2004	EP1480972A2 Compounds possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders
12/01/2004	EP1480961A1 Glutaminyl based dpiv inhibitors
12/01/2004	EP1480959A1 Piperazine derivatives as anti-inflammatory agents
12/01/2004	EP1480954A1 Vanilloid receptor modulators

1 ... 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 ... 1833